Ticagrelor: Difference between revisions
Gerald Chi (talk | contribs) m (→Category) |
|||
| Line 13: | Line 13: | ||
==Category== | ==Category== | ||
ADP receptor inhibitors | ADP receptor inhibitors | ||
==FDA Package Insert== | ==FDA Package Insert== | ||
Revision as of 22:07, 11 March 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Jesus Rosario Hernandez, M.D. [2]
For patient information about Ticagrelor, click here.
Synonyms / Brand Names: BRILINTA®
Overview
Ticagrelor (previously known as AZD6140) is a member of a new generation of P2Y12 inhibitors. Chemically, this is a first-in-class member of the cyclo-pentyl-triazolo-pyrimidine (CPTP) family with a mean terminal half-life of approximately 7 h and a median Tmax of 2.6 h. Ticagrelor’s steady-state volume of distribution (87.5 L) indicates it does not extensively distribute into or bind to tissues.[1]
Category
ADP receptor inhibitors
FDA Package Insert
BRILINTA (ticagrelor) tablet
Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages
Mechanism of Action
Like thienopyridines, ticagrelor is only orally available, but in contrast with these pro-drugs, ticagrelor is direct acting, i.e. does not require metabolic activation. In addition, ticagrelor is a reversible P2Y12 inhibitor with more rapid onset and off set of action compared with clopidogrel. Ticagrelor has 2 metabolites. The major ticagrelor metabolite (AR-C124910XX) has a P2Y12 inhibiting activity comparable to the parent compound while a second metabolite (AR-C133913XX) is inactive. Ticagrelor is rapidly and extensively metabolized in the liver by CYP3A4. The P2Y12 receptor is targeted by ticagrelor via a mechanism that is non-competitive with ADP, suggesting the existence of an independent receptor-binding site. Compared with clopidogrel, ticagrelor provides greater and more consistent platelet inhibition.[2][3]
References
- ↑ Wallentin, Lars (August 30, 2009). "Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes". NEJM.
- ↑ H. Spreitzer (February 4, 2008). "Neue Wirkstoffe - AZD6140". Österreichische Apothekerzeitung (in German) (3/2008): 135. Check date values in:
|date=(help) - ↑ Owen, RT, Serradell, N, Bolos, J (2007). "AZD6140". Drugs of the Future. 32 (10): 845–853. doi:10.1358/dof.2007.032.10.1133832.